Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Editas Medicine stock (EDIT)

Buy Editas Medicine stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Editas Medicine is a biotechnology business based in the US. Editas Medicine shares (EDIT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.23 – an increase of 12.63% over the previous week. Editas Medicine employs 265 staff and has a trailing 12-month revenue of around $61.8 million.

Our top picks for where to buy Editas Medicine stock

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Complimentary access to a financial planner

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

How to buy Editas Medicine stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – EDIT. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Editas Medicine stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
OPTO
Finder Score: 3.8 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.3 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a complimentary access to financial planners.
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
Uphold
Finder Score: 3.6 / 5: ★★★★★
Crypto alternative
Uphold
★★★★★
Cryptocurrency
N/A
$0
4.65%
Get $10
Robinhood
Finder Score: 4.6 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
Public.com
Finder Score: 4.4 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
4.35%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Editas Medicine stock price (NASDAQ: EDIT)

Use our graph to track the performance of EDIT stocks over time.

Editas Medicine shares at a glance

Information last updated 2024-12-05.
Latest market close$2.23
52-week range$1.95 - $11.58
50-day moving average $3.01
200-day moving average $5.02
Wall St. target price$8.15
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-2.55

Is it a good time to buy Editas Medicine stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Editas Medicine price performance over time

Historical closes compared with the close of $2.14 from 2024-12-06

1 week (2024-12-03) 8.08%
1 month (2024-11-11) -35.15%
3 months (2024-09-10) -43.24%
6 months (2024-06-10) -59.77%
1 year (2023-12-08) -79.64%
2 years (2022-12-09) -77.35%
3 years (2021-12-10) 29.01
5 years (2019-12-10) 30.69

Editas Medicine financials

Revenue TTM $61.8 million
Gross profit TTM $-155,246,000
Return on assets TTM -34.32%
Return on equity TTM -78.56%
Profit margin 0%
Book value $2.13
Market Capitalization $164.3 million

TTM: trailing 12 months

Editas Medicine share dividends

We're not expecting Editas Medicine to pay a dividend over the next 12 months.

Editas Medicine share price volatility

Over the last 12 months, Editas Medicine's shares have ranged in value from as little as $1.95 up to $11.58. A popular way to gauge a stock's volatility is its "beta".

EDIT.US volatility(beta: 2.01)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Editas Medicine's is 2.006. This would suggest that Editas Medicine's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Editas Medicine overview

Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases.

Frequently asked questions

null
What percentage of Editas Medicine is owned by insiders or institutions?
Currently 0.321% of Editas Medicine shares are held by insiders and 71.08% by institutions.
How many people work for Editas Medicine?
Latest data suggests 265 work at Editas Medicine.
When does the fiscal year end for Editas Medicine?
Editas Medicine's fiscal year ends in December.
Where is Editas Medicine based?
Editas Medicine's address is: 11 Hurley Street, Cambridge, MA, United States, 02141
What is Editas Medicine's ISIN number?
Editas Medicine's international securities identification number is: US28106W1036
What is Editas Medicine's CUSIP number?
Editas Medicine's Committee on Uniform Securities Identification Procedures number is: 28106W103

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site